IPO
The firm has submitted its xR assay to the FDA and is prioritizing its entry into the minimal residual disease space.
The inclusion of institutional investors in the firm's recent $277 million Series D financing round positions it well for an IPO, should it choose that path.
Tempus AI Prices $410.7M Initial Public Offering
The oncology data company priced its initial public offering of 11.1 million shares at $37.00 per share.
Tempus AI Files for Initial Public Offering
The company's flagship technology is the Tempus Platform, which has allowed it to amass a library of clinical and molecular oncology data.
One near-term indicator of Grail's prospects could come if the firm submits data on the first year of its NHS study to the UK government.
Oct 27, 2022
Aug 29, 2022
MGI Tech Planning to go Public in $366M Chinese IPO
Dec 30, 2021
Top 10 Articles on GenomeWeb in 2021
Oct 8, 2021
IsoPlexis Raises $125M in IPO
Sep 2, 2021
Cue Health Files for IPO for up to $100M
Aug 27, 2021
SeqLL to Go Public in $13M IPO
Jul 19, 2021